Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus. However, the most convincing evidence was obtained in subjects with established cardiovascular (CV) disease. We analyzed the determinants...

Descripción completa

Detalles Bibliográficos
Autores principales: Piccini, Sara, Favacchio, Giuseppe, Panico, Cristina, Morenghi, Emanuela, Folli, Franco, Mazziotti, Gherardo, Lania, Andrea Gerardo, Mirani, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039680/
https://www.ncbi.nlm.nih.gov/pubmed/36966321
http://dx.doi.org/10.1186/s12933-023-01800-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039680/
https://www.ncbi.nlm.nih.gov/pubmed/36966321
http://dx.doi.org/10.1186/s12933-023-01800-z

Ejemplares similares